Keyword: Boston Scientific
Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.
InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.
Boston Scientific has moved to acquire Vertiflex, for $465 million upfront plus three years of milestone payments.
Boston Scientific received approval for its heart valve on the eve of its first-quarter report and after the FDA halted its sales of surgical mesh.
The two remaining U.S. manufacturers of transvaginal surgical mesh have been ordered by the FDA to halt the sale and distribution of those products.
The Federal Trade Commission is requesting additional information from Boston Scientific and BTG ahead of their proposed $4.2 billion deal.
Boston Scientific redesigned its mesh implant for relieving stress urinary incontinence in men, to make it more available to a broader population.
In January, Boston Scientific paid $90 million for a portion of Millipede's shares. Now, it's picking up the rest for $325 million.
The Theranos saga has made strong showings on our past lists of the most-read stories—but this year will be its last, as the company finally bled dry.
While the vast majority of Evaluate’s top-10 list are predicted to hold their relative rankings through 2024, Boston Scientific joins BD as the only two to move forward, displacing General Electric at spot number nine with its healthy appetite for M&A deals.